A study evaluating safety of Tocilizumab, IL-1 inhibitors Anakinra & Canakinumab and Etanercept in patients with Juvenile Idiopathic Arthritis

Next Previous
Trial Profile

A study evaluating safety of Tocilizumab, IL-1 inhibitors Anakinra & Canakinumab and Etanercept in patients with Juvenile Idiopathic Arthritis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Anakinra (Primary) ; Canakinumab (Primary) ; Etanercept (Primary) ; Tocilizumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions

    • Most Recent Events

    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 24 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top